{
    "clinical_study": {
        "@rank": "133028", 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerance of adefovir dipivoxil and indinavir administered orally\n      in combination with zidovudine, lamivudine, or stavudine in HIV-infected patients with CD4\n      cell counts >= 100 cells/mm3 and an HIV-1 RNA baseline copy number >= 5000 copies/ml. To\n      determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of\n      detection (500 copies/ml) by 20 weeks of study therapy and the average reduction in HIV-1\n      RNA from baseline through study week 20. To evaluate the durability of the antiviral\n      response through 48 weeks of study in patients who continue on study therapy after week 24."
        }, 
        "brief_title": "The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This protocol is a stratified, randomized, open-label study of the safety and efficacy of\n      adefovir dipivoxil with indinavir as quadruple therapy in combination with zidovudine and\n      lamivudine, or as triple combination administered with either zidovudine or lamivudine or\n      stavudine for 48 weeks in the treatment of HIV-infected patients with CD4 cell counts >=\n      100/mm3 and an HIV-1 RNA baseline copy number >= 5000 copies/ml. Patients will be randomized\n      to adefovir dipivoxil, indinavir, zidovudine, and lamivudine or adefovir dipivoxil,\n      indinavir, and a nucleoside inhibitor (randomly assigned to receive zidovudine, lamivudine,\n      or stavudine) or to indinavir, zidovudine, and lamivudine. Additionally, a daily dose of\n      L-carnitine will be administered to all patients randomized to an arm containing adefovir\n      dipivoxil."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Laboratory diagnosis of HIV infection (positive HIV antibody test confirmed by\n             Western blot, p24 antigen assay, HIV-1 RNA, or HIV-1 culture).\n\n          -  An HIV-1 RNA plasma titer >= 5000 copies/ml within 14-21 days prior to the baseline\n             visit.\n\n          -  CD4 cell count >= 100 cells/mm3 within 14-21 days prior to the baseline visit.\n\n          -  A minimum life expectancy of at least 1 year.\n\n          -  Signed, informed consent from parent or legal guardian for those patients < 18 years\n             of age.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with any of the following symptoms and conditions are excluded:\n\n          -  Active, serious infections (other than HIV infection) requiring parenteral antibiotic\n             or antiviral therapy. Patients will be considered recovered from such infectious\n             episodes if at least 2 weeks elapsed following the cessation of parenteral therapy\n             before the baseline visit.\n\n          -  Exhibiting evidence of a gastrointestinal malabsorption syndrome or chronic nausea or\n             vomiting which may confer an inability to receive an orally administered medication.\n\n          -  Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma.\n             Patients with biopsy-confirmed cutaneous KS are eligible, but must not have received\n             any systemic therapy for KS within 4 weeks prior to baseline and are not anticipated\n             to require systemic therapy during the study.\n\n          -  Any other clinical condition that in the opinion of the investigator would make the\n             patient unsuitable for study or unable to comply with the dosing requirements.\n\n        Patients with any of the following prior conditions are excluded:\n\n          -  A new AIDS-defining event diagnosed within 1 month prior to baseline.\n\n          -  Any patient who has previously been discontinued from zidovudine, lamivudine, and/or\n             stavudine due to a drug-related toxicity.\n\n          -  Significant history of peripheral neuropathy.\n\n             1. Treatment with immunomodulating agents such as systemic corticosteroids, IL-2, or\n             interferons.\n\n          -  Saquinavir, ritonavir, nelfinavir, nevirapine, delavirdine, didanosine,\n             dideoxycytidine, interferon alpha, interferon beta, isoniazid, rifampin,\n             investigational agents (except upon Sponsor approval), chemotherapeutic agents\n             (systemic), terfenadine, astemizole, cisapride, triazolam, and midazolam.\n\n             1. Prior use of adefovir dipivoxil.\n\n          -  Prior non-protease antiretroviral therapy (other than antiretroviral vaccines) for\n             greater than 4 cumulative weeks.\n\n          -  Prior use of any antiretroviral protease inhibitor.\n\n          -  Immunizations within 30 days of baseline.\n\n          -  Antiretroviral vaccine therapy within 60 days of baseline.\n\n          -  Treatment in the 4 weeks prior to baseline, with immunomodulating agents such as\n             systemic corticosteroids, IL-2, or interferons.\n\n          -  Any other investigational drug within 30 days prior to baseline.\n\n          -  Any prior therapy that, in the opinion of the investigator, would make the patient\n             unsuitable for study or unable to comply with the dosing  requirements.\n\n        Patients with current alcohol or substance abuse judged by the investigator to potentially\n        interfere with patient compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002379", 
            "org_study_id": "232D"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Levocarnitine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Adefovir dipivoxil", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carnitine", 
                "Zidovudine", 
                "Stavudine", 
                "Adefovir", 
                "Adefovir dipivoxil", 
                "Lamivudine", 
                "Indinavir", 
                "Anti-HIV Agents", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "Administration, Oral", 
            "Acquired Immunodeficiency Syndrome", 
            "Zidovudine", 
            "Stavudine", 
            "HIV Protease Inhibitors", 
            "CD4 Lymphocyte Count", 
            "Lamivudine", 
            "Indinavir", 
            "RNA, Viral", 
            "Adenine", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Phoenix Body Positive"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "AIDS Healthcare Foundation Labs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94114"
                    }, 
                    "name": "Davies Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenwich", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06830"
                    }, 
                    "name": "Blick Med Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20037"
                    }, 
                    "name": "George Washington Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Cook County Gen Hosp / Division of Infect Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brookline", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02445"
                    }, 
                    "name": "Community Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10001"
                    }, 
                    "name": "Community Research Initiative on AIDS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Saint Vincent's AIDS Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Hershey Med Ctr / Dept of Hematology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pawtucket", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02860"
                    }, 
                    "name": "Mem Hosp of Rhode Island"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75235"
                    }, 
                    "name": "Univ of Texas Southwestern Med Ctr of Dallas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "Swedish Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ponce", 
                        "country": "Puerto Rico", 
                        "zip": "00731"
                    }, 
                    "name": "Hosp Regional de Ponce - Area Vieja"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "official_title": "A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination With Zidovudine, Lamivudine, or Stavudine for the Treatment of Therapy Naive HIV-Infected Patients With CD4 Cell Counts >= 100 Cells/mm3 and HIV-1 RNA Copy Numbers >= 5,000 Copies/Ml", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002379"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1998"
    }, 
    "geocoordinates": {
        "AIDS Healthcare Foundation Labs": "34.052 -118.244", 
        "Blick Med Associates": "41.039 -73.614", 
        "Community Research Initiative": "42.332 -71.121", 
        "Community Research Initiative on AIDS": "40.714 -74.006", 
        "Cook County Gen Hosp / Division of Infect Diseases": "41.878 -87.63", 
        "Davies Med Ctr": "37.775 -122.419", 
        "George Washington Med Ctr": "38.895 -77.036", 
        "Hershey Med Ctr / Dept of Hematology": "40.286 -76.65", 
        "Hosp Regional de Ponce - Area Vieja": "18.011 -66.614", 
        "Johns Hopkins Univ School of Medicine": "39.29 -76.612", 
        "Mem Hosp of Rhode Island": "41.879 -71.383", 
        "Phoenix Body Positive": "33.448 -112.074", 
        "Saint Vincent's AIDS Ctr": "40.714 -74.006", 
        "Swedish Med Ctr": "47.606 -122.332", 
        "Univ of Texas Southwestern Med Ctr of Dallas": "32.803 -96.77"
    }
}